Aurinia Pharmaceuticals

55 articles with Aurinia Pharmaceuticals

• Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021

  7/26/2021

  Aurinia Pharmaceuticals Inc. announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021, after the markets close.

• Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange

  7/16/2021

  Aurinia Pharmaceuticals Inc., a commercial stage biopharmaceutical company advancing therapies for severe autoimmune diseases, announced it will voluntarily delist the common shares of the Company from the Toronto Stock Exchange effective as of the close of trading on July 30, 2021.

• Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs

  6/30/2021

  Aurinia Pharmaceuticals Inc. announced the recipients of five $50,000 grant awards to support implementation patient navigation programs targeted toward disadvantaged populations at most risk of developing SLE and LN.

• Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)

  6/25/2021

  Aurinia Pharmaceuticals Inc. announced that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd., filed an initial Marketing Authorization Application for voclosporin for the treatment of lupus nephritis to the European Medicines Agency. LN is a complication of the autoimmune disease systemic lupus erythematosus that seriously impacts the kidneys.

• Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors

  6/14/2021

  Aurinia Pharmaceuticals Inc. announced the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors effective June 14, 2021.

• Aurinia Announces Results of the 2021 Annual General Meeting

  6/8/2021

  Aurinia Pharmaceuticals Inc. is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting held on June 7, 2021.

• Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress

  6/7/2021

  New examination of AURORA 1 Phase 3 data demonstrates increased renal response rates with LUPKYNIS™ (voclosporin) used in combination with MMF and low-dose steroids in patients with lupus nephritis regardless of target urine protein creatinine ratio (UPCR)

• 

  A New $550 Million Life Sciences Venture Capital Fund is in Town

  6/3/2021

  venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.

• Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference - May 27, 2021

  5/27/2021

  Aurinia Pharmaceuticals Inc. announced that members of the executive management team will participate in a fireside chat during the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 11:30 a.m. ET.

• Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis

  5/20/2021

  Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS ™ (voclosporin) in Subjects with Lupus Nephritis - Individuals treated with LUPKYNIS sustained meaningful reductions in proteinuria with no change in mean eGFR at 104 weeks of treatment -

• Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences - May 14, 2021

  5/14/2021

  Aurinia Pharmaceuticals Inc. announced that members of the executive management team will participate in two upcoming investor conferences

• Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis

  5/10/2021

  Company-sponsored program seeks proposals to help patients in the U.S. make informed health choices and support underserved populations with these conditions

• Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet

  5/10/2021

  Study results demonstrate that LUPKYNIS in combination with typical standard of care (SoC) led to statistically superior complete renal response rates compared to treatment with SoC alone

• Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights

  5/6/2021

  Quarter highlights include FDA approval, launch and early market penetration of LUPKYNIS™ as the first approved oral therapy for lupus nephritis (LN)

• Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021

  4/28/2021

  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021, after the markets close. Aurinia’s management team will also host a conference call at 5:00 p.m. EDT to discuss the Company’s financial results and to provide a general business update.

• Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

  4/15/2021

  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 2:30 p.m. ET.

• Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings

  4/8/2021

  Additional efficacy data from pooled analysis of AURA-LV and AURORA 1 pivotal trials demonstrate potential to improve renal response regardless of disease progression at diagnosis

• Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report

  3/15/2021

  Aurinia Pharmaceuticals Inc. announced a favorable assessment regarding the cost-effectiveness and value of LUPKYNIS™, based on an independent analysis issued by the Institute for Clinical and Economic Review in a revised Evidence Report issued on March 12, 2021.

• Aurinia Pharmaceuticals to Present at Three Upcoming March 2021 Investor Conferences

  3/2/2021

  Aurinia Pharmaceuticals Inc. announced that members of the executive management team will participate in multiple upcoming investor conferences

• Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights

  2/24/2021

  - LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - Cash, cash equivalents, and investments of $423 million at December 31, 2020 – - Conference call to be hosted today at 4:30 p.m. ET -